Comparison of Cypher Select and Taxus Express Coronary Stents - Full Text View

Purpose

Randomized nine months clinical comparison of implantation of Taxol eluting (Taxus Express) and Sirolimus eluting (Cypher Select) stents in non-selected patients with coronary artery disease.

Condition	Intervention	Phase
Coronary Artery Disease Angina Pectoris	Procedure: Percutaneous coronary intervention (PCI)	Phase IV

MedlinePlus related topics:

Angina Coronary Artery Disease

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety Study

Official Title:	Randomized Clinical Comparison of Cypher Select and Taxus Express Stent Implantation in Unselected Patients With Coronary Artery Disease.

Further study details as provided by Skejby Hospital:

Primary Outcome Measures:

MACE (cardiac death, MI, TVR, TLR, TVF)during 9 months

Secondary Outcome Measures:

Total death after 9 months, 2 and 3 years
Cardiac death after 9 months, 2 and 3 years
MI after 9 months, 2 and 3 years
TVL, TVR, TVF after 9 months, 2 and 3 years
Stent thrombosis after 9 months, 2 and 3 years

Estimated Enrollment:	2000
Study Start Date:	August 2004
Estimated Study Completion Date:	January 2009

Detailed Description:

Design:

Randomized open multicentre trial.

Patients:

1800 patients with coronary artery disease scheduled for percutaneous coronary intervention with stent implantation.

Inclusion criteria:

Patients with coronary artery disease scheduled for percutaneous coronary intervention with stent implantation.
Signed informed conscent.

Exclusion critteria:

Participation in other stent studies.

Randomization:

Implantation of Taxus Express og Cypher Select stents.

Primary end-point:

Combined end-point of cardiac death, new revascularization (PCI or CABG) or myocardial infarction after nine months.

Secondary end-påoints:

Total death after nine months
Cardiac death after nine months
Myocardial infarction after nine months
Index vessel myocardial infarction after nine months
Target lesion revascularization
Target vessel revascularization
Stent thrombosis after nine months

End-point evaluation:

End-points will be ajudicated by an independent end-point committee

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Planned implantation of drug eluting stent
Written informed consent

Exclusion Criteria:

Planned intervention with other stents than study stents

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388934

Sponsors and Collaborators

Skejby Hospital

University of Aarhus

University of Copenhagen

Odense University Hospital

Investigators


Principal Investigator:	Anders Galloe, MD	Gentofte Hospital, Copenhagen

More Information

Publications indexed to this study:

Galløe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrøm SZ, Stephansen GB, Lassen JF; SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008 Jan 30;299(4):409-16.

Study ID Numbers:	SORT-OUT II
First Received:	October 16, 2006
Last Updated:	May 8, 2007
ClinicalTrials.gov Identifier:	NCT00388934
Health Authority:	Denmark: National Board of Health

Keywords provided by Skejby Hospital:

Percutaneous coronary intervention

Angina pectoris

Stent

Study placed in the following topic categories:

Arterial Occlusive Diseases

Coronary Disease

Signs and Symptoms

Heart Diseases

Myocardial Ischemia

Vascular Diseases

Angina Pectoris

Pain

Arteriosclerosis

Ischemia

Coronary Artery Disease

Chest Pain

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 18, 2008

Sponsors and Collaborators:	Skejby Hospital University of Aarhus University of Copenhagen Odense University Hospital
Information provided by:	Skejby Hospital
ClinicalTrials.gov Identifier:	NCT00388934